◆英語タイトル:Pharming Group NV (PHARM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10096
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Pharming Group NV (Pharming) is a specialty pharmaceutical company which develops nutritional products for the treatment of genetic diseases and unmet medical needs. The company’s flagship product, Ruconest (Rhucin in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema (HAE). Its product pipeline consists of recombinant human C1 inhibitor (rhC1INH) for the treatment of delayed graft function; and recombinant human factor VIII (rhFactor VIII) for the treatment of haemophilia A. The company has manufacturing facilities in the Netherlands and the US. It markets and sells its products through distributors and partners. Pharming is headquartered in Leiden, the Netherlands.
Pharming Group NV (PHARM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pharming Group NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Pharming Group NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pharming Group NV, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Pharming Acquires Rights to Ruconest from Valeant Pharma for USD125 Million 11
Pharming Group Acquires Certain Assets of Transgenic Rabbit Models 13
Partnerships 15
Pharming Group Enters Into Co-Marketing Agreement With Hyupjin For Ruconest 15
Pharming Group Enters Into Co-Marketing Agreement With Transmedic For Ruconest 16
Equity Offering 17
Pharming Group to Raise Funds through Private Placement of Shares upon Exercise of Warrants 17
Pharming Raises USD9.2 Million in Rights Offering of Shares 18
Pharming Raises USD20.3 Million in Private Placement of Shares 20
Pharming Announces Private Placement Of Shares For US$16 Million 21
Pharming Group Raises USD0.2 Million in Private Placement of Additional Shares 23
Debt Offering 25
Pharming Raises USD13 Million in Private Placement of 8.5% Bonds 25
Pharming Raises USD48 Million in Private Placement of Bonds 27
Pharming Group Announces Private Placement Of Bonds For US$22 Million 29
Pharming Group NV – Key Competitors 30
Pharming Group NV – Key Employees 31
Pharming Group NV – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Oct 25, 2018: Pharming Group reports interim financial results for the first nine months of 2018 33
Jul 26, 2018: Pharming reports on financial results for the first half of 2018 35
May 17, 2018: Pharming Group Interim Report on Financial Results for the First Quarter 2018 37
Mar 07, 2018: Pharming Group Report on Preliminary Financial Results for 2017 39
Oct 26, 2017: Pharming Group reports financial results for the first nine months of 2017 41
Jul 27, 2017: Pharming Reports on Financial Results for the First Half of 2017 42
May 17, 2017: Pharming Group Interim Report on Financial Results for the First Quarter 2017 47
Mar 09, 2017: Pharming Group: Report on Preliminary Financial Results for 2016 49
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51
List of Tables
Pharming Group NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pharming Group NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pharming Group NV, Deals By Therapy Area, 2012 to YTD 2018 8
Pharming Group NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pharming Acquires Rights to Ruconest from Valeant Pharma for USD125 Million 11
Pharming Group Acquires Certain Assets of Transgenic Rabbit Models 13
Pharming Group Enters Into Co-Marketing Agreement With Hyupjin For Ruconest 15
Pharming Group Enters Into Co-Marketing Agreement With Transmedic For Ruconest 16
Pharming Group to Raise Funds through Private Placement of Shares upon Exercise of Warrants 17
Pharming Raises USD9.2 Million in Rights Offering of Shares 18
Pharming Raises USD20.3 Million in Private Placement of Shares 20
Pharming Announces Private Placement Of Shares For US$16 Million 21
Pharming Group Raises USD0.2 Million in Private Placement of Additional Shares 23
Pharming Raises USD13 Million in Private Placement of 8.5% Bonds 25
Pharming Raises USD48 Million in Private Placement of Bonds 27
Pharming Group Announces Private Placement Of Bonds For US$22 Million 29
Pharming Group NV, Key Competitors 30
Pharming Group NV, Key Employees 31
Pharming Group NV, Subsidiaries 32
List of Figures
Pharming Group NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pharming Group NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8